The bridge is real; the pathway is not automatic

For academic start-ups, the ideas established so far support one practical judgment: becoming a company and becoming able to finance the next stage are different achievements. The first depends on whether a research-based project can survive long enough to be formalised; the second depends on whether the resulting venture has the technical proof, commercial capability, and relationships needed by its next source of capital. Keeping those bottlenecks separate makes the evidence more useful and prevents a strong early grant result from being mistaken for a guarantee of later growth.

Two bottlenecks, one financing path

The first bottleneck is existence. Before incorporation, a project may have scientific promise but no company able to sign contracts, hire people, raise equity, or sell a product. Founders may need to leave paid research work, buy materials, or test a prototype before they know whether the commercial route is viable. The German EGS evaluation speaks directly to this state. Near its expert-score funding threshold, projects receiving the programme’s support were much more likely to appear as qualifying companies in the Commercial Register than close projects that did not receive the intervention.

The second bottleneck is financeability. Once a company exists, its problem changes. It must show not only that the science can work, but that a customer, partner, investor, or acquirer can understand the route from technical progress to economic return. The founding team may need business skills and industry contacts. The technology may need more development than a private investor wants to fund at once. A first round that solves the runway problem can leave these commercial interfaces untouched.

These bottlenecks are linked, but they are not a ladder on which one success automatically produces the next. Company formation creates the legal and organisational vehicle for future financing; it does not create future demand, a credible valuation, or an investor network. Likewise, the absence of a later equity round does not prove that the early grant was wasted if the grant’s relevant objective was to prevent a promising project from ending before incorporation.

flowchart LR A["Research-stage project"] --> B{"Pre-foundation bottleneck"} B -->|early grant or assistance| C["Formal company"] B -->|no effective bridge| D["No company entry"] C --> E["First funding modality"] E --> F{"Post-formation bottleneck"} F -->|technical and commercial proof| G["Follow-on options"] F -->|missing capability or network| H["Narrower path or no follow-on"] G --> I["Scale-up or exit"]

The model also clarifies why academic start-ups are exposed to both sides of the problem. Their research proximity can produce more original, radical, and science-linked patents, but their technologies may be harder to evaluate or integrate. Their founders may have deep specialist knowledge and strong academic networks while having fewer direct relationships with customers, operators, or private investors. A grant can buy time to address the first problem. A support programme, commercial partner, or later equity investor may be needed to address the second.

That is the meaning of a financing path. It is not a fixed sequence that every venture must follow, and it is not a ranking in which equity is always superior to a grant. It is a set of transitions in which each funding choice changes the venture’s resources, obligations, ownership, relationships, and evidence.